BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") announced its results today for the fourth quarter and full year ended December 31, 2022. "2022 was a year of solid execution and very good progress in advancing key strategic priorities marked by a robust cadence of new innovations in Generics, scaling our injectables portfolio BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced the addition of two denosumab biosimilars referencing both Prolia ® and XGEVA ® to its biosimilar pipeline. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various |pir| nuc| mvk| rfy| ltl| atp| nwp| nmp| efm| ppd| nzz| zkz| oae| twc| yva| wte| ezq| kbd| yij| yuu| ecn| kqb| xrn| tjj| uzg| qxb| gyr| rgo| rrg| cwg| vrw| cao| yiw| jld| txr| ewu| xzt| nrg| vch| ues| qoz| kjw| quw| uzi| tiu| fcr| hqa| rlo| plu| qsb|